Major Ivermectin Study Omitted Hundreds of Participants, Researchers Say
By Zachary Stieber A large study examining ivermectin against COVID-19 included more participants than was reported in 2023, researchers acknowledged in a new correction. A U.S. government-funded trial arm examining ivermectin was said to have included 1,206 participants, including 602 who received ivermectin. The actual number of participants was 1,432, with 708 receiving ivermectin, Dr.
More Stories
Invesco NASDAQ 100 ETF (NASDAQ:QQQM) Shares Bought by Mount Lucas Management LP
Mount Lucas Management LP lifted its position in shares of Invesco NASDAQ 100 ETF (NASDAQ:QQQM – Free Report) by 28.6%...
Columbus McKinnon Co. (NASDAQ:CMCO) Shares Sold by GoalVest Advisory LLC
GoalVest Advisory LLC cut its holdings in Columbus McKinnon Co. (NASDAQ:CMCO – Free Report) by 2.0% during the third quarter,...
ECARX Holdings Inc. (NASDAQ:ECX) Sees Significant Growth in Short Interest
ECARX Holdings Inc. (NASDAQ:ECX – Get Free Report) was the recipient of a significant increase in short interest during the...
Great Elm Capital Corp. 8.75% Notes due 2028 (NASDAQ:GECCZ) Short Interest Update
Great Elm Capital Corp. 8.75% Notes due 2028 (NASDAQ:GECCZ – Get Free Report) was the recipient of a large increase...
iShares GNMA Bond ETF (NASDAQ:GNMA) Short Interest Update
iShares GNMA Bond ETF (NASDAQ:GNMA – Get Free Report) was the recipient of a significant growth in short interest during...
KORU Medical Systems (NASDAQ:KRMD) Price Target Raised to $3.50 at Piper Sandler
KORU Medical Systems (NASDAQ:KRMD – Free Report) had its price objective upped by Piper Sandler from $3.00 to $3.50 in...